title: Establishment and characterization of a novel ovarian serous adenocarcinoma cell line, TU-OS-4, that overexpresses EGFR and HER2.
abstract: A new line of human ovarian serous adenocarcinoma cells, TU-OS-4, was established and characterized. The cells showed a short, spindle-shaped morphology and grew in monolayers without contact inhibition while forming an arrangement resembling a jigsaw puzzle. Chromosome numbers ranged from 55 to 73. The proliferation rate was lower than other serous adenocarcinoma cell lines tested (KF, SHIN-3, and SK-OV-3), and the doubling time was 53.3 h. Western blot analysis showed that TU-OS-4 cells overexpressed epidermal growth factor receptor, human epidermal growth factor receptor (HER) 2, and phosphorylated HER2 protein. The IC(50) values to cisplatin, paclitaxel, and lapatinib were 25.8 μM, 686 nM, and 183 nM, respectively. Heterotransplantation in nude mice reflected the original tumor of the cells. These results suggested that this cell line would be useful to study chemoresistant mechanisms and contribute to establishing novel treatment strategies for patients with ovarian cancer.
authors.affiliation: Department of Obstetrics and Gynecology, Tottori University School of Medicine, 36-1 Nishicho, Yonago 683-8504, Japan. itamochi@hotmail.com
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Itamochi
authors.forename: Misaki
authors.initials: M
authors.lastname: Kato
authors.forename: Mayumi
authors.initials: M
authors.lastname: Nishimura
authors.forename: Tetsuro
authors.initials: T
authors.lastname: Oishi
authors.forename: Muneaki
authors.initials: M
authors.lastname: Shimada
authors.forename: Shinya
authors.initials: S
authors.lastname: Sato
authors.forename: Jun
authors.initials: J
authors.lastname: Naniwa
authors.forename: Seiya
authors.initials: S
authors.lastname: Sato
authors.forename: Michiko
authors.initials: M
authors.lastname: Nonaka
authors.forename: Akiko
authors.initials: A
authors.lastname: Kudoh
authors.forename: Naoki
authors.initials: N
authors.lastname: Terakawa
authors.forename: Junzo
authors.initials: J
authors.lastname: Kigawa
authors.forename: Tasuku
authors.initials: T
authors.lastname: Harada
mesh_terms: D000368:Aged; D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D018284:Cystadenocarcinoma, Serous / Q000235:genetics* / Q000473:pathology*; D003584:Cytological Techniques / Q000379:methods*; D019008:Drug Resistance, Neoplasm; D066246:ErbB Receptors / Q000235:genetics / Q000378:metabolism*; D005260:Female; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D006801:Humans; D000077341:Lapatinib; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D010051:Ovarian Neoplasms / Q000235:genetics* / Q000473:pathology*; D011799:Quinazolines / Q000494:pharmacology; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000235:genetics / Q000378:metabolism*; D015398:Signal Transduction / Q000235:genetics; D023041:Xenograft Model Antitumor Assays
chemical_list: D000970:Antineoplastic Agents; D066246:ErbB Receptors; D000077341:Lapatinib; D011799:Quinazolines; D018719:Erb-b2 Receptor Tyrosine Kinases; C512478:EGFR protein, human; C508053:ERBB2 protein, human